• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Teatis, low-sugar superfood powders developer for diabetics, closes seed round

September 9, 2021 by David Barret Leave a Comment

A serial entrepreneur Hiroshi Takatoh recognized the need for convenient and nutritious food for critically ill consumers after losing his late wife to cancer.

Takatoh founded Teatis, a plant-based sugar blocking superfood powder for diabetic consumers, in 2017 in stealth mode and went fully operational in April 2021 by teaming up with a group of doctors and registered nutritionists.

Teatis announced today it has raised $700,000 seed funding to advance its growth in the US market.  The seed money brings Teatis’ total funding to over $1million.

The seed round was led by Genesia Ventures, Ryo Ishizuka, a former CEO and co-founder of Japanese e-commerce company Mercari and Takuya Noguchi, CEO and founder of Japan’s skincare brand BULK HOMME. Seven other angel investors also participated in the seed funding.

Teatis will use the seed money for production and marketing in the US, where 122 million diabetics and pre-diabetics continue to work for prevention and treatment against diabetes, CEO and co-founder of Teatis Hiroshi Takatoh told TechCrunch. The company is now focusing on the US market where its production is located while its next funding, a Series A, is set for next year, Takatoh added.

“Most of our consumers, about 88%, are diabetics, and our recipe is built to help diabetics manage their blood sugar. A staggering number of Americans suffer from diabetes, and there is significant demand for diabetic-friendly foods that are nutritious, convenient and functional,” Takatoh said.

Teatis develops a supplement for all consumers interested in low-sugar foods, as well as pre-diabetics, Takatoh said. Teatis’ plant-based powders does not contain chemicals or sweeteners but include a special Japanese ingredient such as brown seaweed extract (Arame) that is proven to suppress the absorption of sugar from the intestinal tract and reduce blood sugar levels. The low-sugar powder can be made into teas, lattes or added to smoothies.

Oviva grabs $80M for app-delivered healthy eating programs

The US meal placement market size for diabetes is estimated at $5 billion while the US consumer packaged foods market for diabetes is approximately $300 billion, Takatoh said.

“We combine food science and technology to solve problems for diabetics through food products and telehealth,” Takatoh said.

With its plan on building out a comprehensive one-stop shop for diabetic health, Teatis will launch a Registered Dietitian platform, Teatis RD on Demand, this month, to offer a full-service such as food products, telehealth, and recipes, for those battling diabetes.

Teatis RD on Demand will provide private, 1-on-1 sessions with registered dietitians. It will start at $29 per 30 minutes, which is a reduced cost, versus traditional offline appointments that cost $150 per 30 minutes, and Teledoc, which costs $90 per 30 minutes, according to Takatoh.

“Many existing players in space are old companies that don’t have digital competency and data-driven production methods. Mr. Takatoh is a proven serial entrepreneur with the qualities and boldness to take over the market…I’m excited to see how Teatis’ great ideas and products will help many people who are suffering from diabetes and other chronic diseases in the future,” Genesia Ventures Manager Shunsuke Sagara said.

Oviva scores $21M Series B to bring its digital diabetes treatment to more of Europe

Plant-based cereal startup OffLimits pours $2.3M into new products

Source Link Teatis, low-sugar superfood powders developer for diabetics, closes seed round

David Barret
David Barret

Related posts:

  1. Hackers are hiring more English speakers to write believable email scams
  2. JBL Quantum 350 looks like a great affordable wireless gaming headset
  3. Canada trade surplus narrowed in July to C$778 million
  4. Life insurers shift to pre-pandemic norms after COVID vaccine roll-outs

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • US Just Killed NASA’s Mars Sample Return Mission – So What Happens Now?
  • Art Sleuths May Have Recovered Traces Of Da Vinci’s DNA From One Of His Drawings
  • Countries With The Most Narcissists Identified By 45,000-Person Study, And The Results Might Surprise You
  • World’s Oldest Poison Arrows Were Used By Hunters 60,000 Years Ago
  • The Real Reason You Shouldn’t Eat (Most) Raw Cookie Dough
  • Antarctic Scientists Have Just Moved The South Pole – Literally
  • “What We Have Is A Very Good Candidate”: Has The Ancestor Of Homo Sapiens Finally Been Found In Africa?
  • Europe’s Missing Ceratopsian Dinosaurs Have Been Found And They’re Quite Diverse
  • Why Don’t Snorers Wake Themselves Up?
  • Endangered “Northern Native Cat” Captured On Camera For The First Time In 80 Years At Australian Sanctuary
  • Watch 25 Years Of A Supernova Expanding Into Space Squeezed Into This 40-Second NASA Video
  • “Diet Stacking” Trend Could Be Seriously Bad For Your Health
  • Meet The Psychedelic Earth Tiger, A Funky Addition To “10 Species To Watch” In 2026
  • The Weird Mystery Of The “Einstein Desert” In The Hunt For Rogue Planets
  • NASA Astronaut Charles Duke Left A Touching Photograph And Message On The Moon In 1972
  • How Multilingual Are You? This New Language Calculator Lets You Find Out In A Minute
  • Europa’s Seabed Might Be Too Quiet For Life: “The Energy Just Doesn’t Seem To Be There”
  • Amoebae: The Microscopic Health Threat Lurking In Our Water Supplies. Are We Taking Them Seriously?
  • The Last Dogs In Antarctica Were Kicked Out In April 1994 By An International Treaty
  • Interstellar Comet 3I/ATLAS Snapped By NASA’s Europa Mission: “We’re Still Scratching Our Heads About Some Of The Things We’re Seeing”
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2026 · Medical Market Report. All Rights Reserved.

Go to mobile version